Technology
Health
Biotechnology

Syndax Pharmaceuticals

$5.05
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.06 (-1.17%) Today
-$0.06 (-1.17%) Today

Why Robinhood?

You can buy or sell SNDX and other stocks, options, ETFs, and crypto commission-free!

About

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. Read More The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Employees
38
Headquarters
Waltham, Massachusetts
Founded
2005
Market Cap
126.91M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
282.23K
High Today
$5.14
Low Today
$5.00
Open Price
$5.14
Volume
71.22K
52 Week High
$15.20
52 Week Low
$3.39

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Cancer Prevention
Pharmaceutical
2016 IPO

News

Seeking AlphaMar 14

Syndax Pharmaceuticals (SNDX) Investor Presentation - Slideshow

The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with this event. 1 28 Click to enlarge Notes:...

38
Seeking AlphaMar 8

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q4 2018 Results - Earnings Call Transcript

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2018 Results Earnings Conference Call March 7, 2019 4:30 PM ET Company Participants Melissa Forst - Argot Partners, VP Briggs Morrison - CEO Richard Shea - CFO & Treasurer Michael Metzger - President & COO Michael Meyers - Chief Medical Officer & Senior VP Peter Ordentlich - Co-Founder & Chief Scientific Officer Conference Call Participants Christopher Marai - Nomura Instinet Chris Shibutani - Cowen Jake Colby - BTIG David Lebowitz - Morgan Stanley ...

77
PR NewswireMar 7

Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update

WALTHAM, Mass., March 7, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter ended December 31, 2018. In addition, the Company provided a clinical and business update. As of December 31, 2018, Syndax had $80.9 million in cash, cash equivalents and short-term investments. "We expect the coming months to b...

64

Earnings

-$0.96
-$0.86
-$0.77
-$0.67
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.67 per share
Actual
-$0.70 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.